Post hoc analysis of two STAMPEDE trials (1137 patients with high-risk non-metastatic prostate cancer): in AI-defined very high-risk patients, adding abiraterone to ADT improved metastasis-free survival (HR 0.47), with limited benefit in others (HR 0.83).
Secondary analysisn = 1,137
Parker et al. Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer